The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th EditionKalorama Information
January 1, 2012
245 Pages - SKU: KLI6501843
Tyrosine kinase inhibitors such as Gleevac and Nexavar represent the fastest growing segment in the market for cancer treatments and have boosted the performance of many pharmaceutical companies, according to Kalorama Information. The healthcare market research publisher estimated the world market for cancer therapies to be $54.4 billion in 2010 in its latest report, The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition.
"Growth in cancer biotherapies spiked in the last five years, taking share from hormone and chemotherapy sales," said Bruce Carlson, publisher of Kalorama Information. "And within that category, tyrosine kinase inhibitors have demonstrated effectiveness and thus they've been growing fast in terms of sales."
Mutations in receptor tyrosine kinases cause cell proliferation and human disease. Drugs such as Iressa, Tarceva, Tykerb, Sprycel, Tasigna, Sutent and the segment's newest product Votrient, have been shown to inhibit the function of these receptors and thus mitigate the unusual cell growth that represents cancer. Sales will likely remain strong with research and development efforts focused on these newer therapies. In the last five years, Kalorama estimates that tyrosine kinase inhibitors grew by nearly 26.7%, faster than any other cancer treatment.
The report notes that a rising incidence of cancer, particularly in the over 50 population, is likely having a significant impact on all areas of cancer treatment. However, for many cancer types, there remains a significant unmet need in effective treatment. Lung cancer is one example, as patient survival is less than five years after diagnosis. The report covers new therapies that are in development.
More Oncology/Hematology reports by Kalorama Information
More Global Oncology/Hematology reports
- Antibody Technologies
- In Vitro Diagnostics
- Hematology & Oncology
- Research & Development
- Therapeutic Area
- The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
- 2013 Analysis of the PT and APTT Point-of-Care Testing Market: US, Germany, Spain,-Physician Offices, Emergency Rooms, Operating Suites, ICIs/CUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers
- Analytical Tool - Cancer Immunotherapy
- Molecular Diagnostics in Cancer Testing
- Global Next Generation Cancer Diagnostic Devices Market 2012-2016